TORONTO – Spectral Medical Inc. (TSX:EDT), a company specializing in therapies for sepsis and septic shock, is nearing an important milestone in its Tigris trial, a Phase 3 study evaluating the Polymyxin B Hemoperfusion (PMX) device. The trial, which commenced in 2024, has recently accelerated its patient enrollment, with the company announcing that it has screened over 100 patients per week post-holiday season and has enrolled patient number 82 in the first week of January. The Tigris trial aims to assess the efficacy of PMX in treating adults with endotoxemia and septic shock. Spectral Medical reported that the preliminary mortality data at both the 28-day primary endpoint and at one year have so far exceeded the efficacy targets set for…
